UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup

2019 ◽  
Vol 122 ◽  
pp. 91-100
Author(s):  
Véronique D'Hondt ◽  
Jean-Luc Canon ◽  
Lise Roca ◽  
Christelle Levy ◽  
Jean-Yves Pierga ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document